ATE474058T1 - Lentivirale vektoren zur behandlung neurodegenerativer krankheiten - Google Patents

Lentivirale vektoren zur behandlung neurodegenerativer krankheiten

Info

Publication number
ATE474058T1
ATE474058T1 AT01972317T AT01972317T ATE474058T1 AT E474058 T1 ATE474058 T1 AT E474058T1 AT 01972317 T AT01972317 T AT 01972317T AT 01972317 T AT01972317 T AT 01972317T AT E474058 T1 ATE474058 T1 AT E474058T1
Authority
AT
Austria
Prior art keywords
treatment
neurodegenerative diseases
lentiviral vectors
vector genome
genomes
Prior art date
Application number
AT01972317T
Other languages
English (en)
Inventor
Alan John Kingsman
Nicholas Mazarakis
Enca Martin-Rendon
Mimoun Azzouz
Jonathan Rohll
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE474058T1 publication Critical patent/ATE474058T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)
AT01972317T 2000-10-06 2001-10-05 Lentivirale vektoren zur behandlung neurodegenerativer krankheiten ATE474058T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024550.6A GB0024550D0 (de) 2000-10-06 2000-10-06
PCT/GB2001/004433 WO2002029065A2 (en) 2000-10-06 2001-10-05 Retroviral vectors containing internal ribosomal entry sites

Publications (1)

Publication Number Publication Date
ATE474058T1 true ATE474058T1 (de) 2010-07-15

Family

ID=9900826

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972317T ATE474058T1 (de) 2000-10-06 2001-10-05 Lentivirale vektoren zur behandlung neurodegenerativer krankheiten

Country Status (13)

Country Link
US (3) US7259015B2 (de)
EP (2) EP1337655B1 (de)
JP (1) JP4224295B2 (de)
AT (1) ATE474058T1 (de)
AU (1) AU2001292093A1 (de)
CA (1) CA2424738A1 (de)
CY (1) CY1110817T1 (de)
DE (1) DE60142576D1 (de)
DK (1) DK1337655T3 (de)
ES (1) ES2348277T3 (de)
GB (1) GB0024550D0 (de)
PT (1) PT1337655E (de)
WO (1) WO2002029065A2 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588757B2 (en) * 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
ES2634424T3 (es) * 2002-02-01 2017-09-27 Oxford Biomedica (Uk) Limited Vector multicistrónico lentivírico
NZ576445A (en) 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
DK3192874T3 (da) 2008-06-18 2019-12-16 Oxford Biomedica Ltd Virusoprensning
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
WO2010055290A1 (en) * 2008-11-11 2010-05-20 Oxford Biomedica (Uk) Limited Method
WO2011054976A2 (en) * 2009-11-09 2011-05-12 Genepod Therapeutics Ab Novel viral vector construct for neuron specific optimized continuous dopa synthesis in vivo
CN102946907A (zh) * 2010-05-28 2013-02-27 牛津生物医学（英国）有限公司 慢病毒载体向脑的递送
WO2012135389A2 (en) * 2011-03-28 2012-10-04 The Regents Of The University Of California Host cells and methods for oxidizing aromatic amino acids
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US10400252B2 (en) 2011-10-28 2019-09-03 Oxford Biomedica (Uk) Ltd. Catecholamine enzyme fusions
GB201118636D0 (en) * 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
JP6698114B2 (ja) * 2011-10-28 2020-05-27 オックスフォード バイオメディカ （ユーケー） リミテッド 構築物
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2013161958A1 (ja) 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター
US20150224209A1 (en) * 2012-09-14 2015-08-13 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター
EP2931899A1 (de) 2012-12-12 2015-10-21 The Broad Institute, Inc. Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon
BR112015013784A2 (pt) 2012-12-12 2017-07-11 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas
WO2014093965A1 (en) * 2012-12-14 2014-06-19 Case Western Reserve University Genomic rna packaging enhancer element
ES2767318T3 (es) 2013-06-17 2020-06-17 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas
CN105793425B (zh) 2013-06-17 2021-10-26 布罗德研究所有限公司 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
CN107995927B (zh) 2013-06-17 2021-07-30 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
WO2015048690A1 (en) * 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014361784A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders
KR20160089527A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
CA2932472A1 (en) 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
EP3080259B1 (de) 2013-12-12 2023-02-01 The Broad Institute, Inc. Konstruktion von systemen, verfahren und optimierte führungszusammensetzungen mit neuen architekturen zur sequenzmanipulation
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
EP3082853A2 (de) 2013-12-20 2016-10-26 The Broad Institute, Inc. Kombinationstherapie mit neoantigen-impfstoff
DK3180426T3 (da) 2014-08-17 2020-03-30 Broad Inst Inc Genomredigering ved anvendelse af cas9-nickaser
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3212788A2 (de) 2014-10-27 2017-09-06 The Broad Institute, Inc. Zusammensetzungen, verfahren und verwendung von screening auf synthetische tödliche gene
BR112017009497A2 (pt) 2014-11-05 2018-02-06 Voyager Therapeutics, Inc. polinucleotídeos de aadc para o tratamento da doença de parkinson
ES2878451T3 (es) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Polinucleótidos moduladores
EP3985115A1 (de) 2014-12-12 2022-04-20 The Broad Institute, Inc. Geschützte guide-rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3234193B1 (de) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molekulare biomarker für krebsimmuntherapie
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
ES2578903B1 (es) * 2015-01-02 2017-07-07 Instituto De Salud Carlos Iii Vector lentiviral de expresión autolimitada
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
EP3297660A2 (de) 2015-05-20 2018-03-28 The Broad Institute Inc. Gemeinsam genutzte neoantigene
WO2016201368A1 (en) 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
CA3012631A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
EP3436575A1 (de) 2015-06-18 2019-02-06 The Broad Institute Inc. Neuartige crispr-enzyme und -systeme
MX2017016289A (es) 2015-06-18 2018-08-15 Broad Inst Inc Mutaciones de la enzima crispr que reducen los efectos fuera del blanco.
CN108136048A (zh) * 2015-08-03 2018-06-08 米奥多巴有限公司 左旋多巴的系统合成和调节
EP3337908A4 (de) 2015-08-18 2019-01-23 The Broad Institute, Inc. Verfahren und zusammensetzungen zur veränderung der funktion und struktur von chromatinschleifen und/oder -domänen
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US20170211142A1 (en) 2015-10-22 2017-07-27 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3368687B1 (de) 2015-10-27 2021-09-29 The Broad Institute, Inc. Zusammensetzungen und verfahren gegen krebsspezifische sequenzvariationen
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
AU2017253107B2 (en) 2016-04-19 2023-07-20 Massachusetts Institute Of Technology CPF1 complexes with reduced indel activity
EP3445856A1 (de) 2016-04-19 2019-02-27 The Broad Institute Inc. Neuartige crispr-enzyme und -systeme
CA3026055A1 (en) 2016-04-19 2017-10-26 The Broad Institute, Inc. Novel crispr enzymes and systems
KR20240096679A (ko) 2016-04-20 2024-06-26 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
KR20230156150A (ko) 2016-06-17 2023-11-13 더 브로드 인스티튜트, 인코퍼레이티드 제vi형 crispr 오솔로그 및 시스템
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
DK3491384T3 (da) * 2016-08-01 2021-06-28 Health Research Inc Sammensætninger og fremgangsmåder til hurtig kloning af t-celle-receptorer
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
CN110114461A (zh) 2016-08-17 2019-08-09 博德研究所 新型crispr酶和系统
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
SG11201901718VA (en) * 2016-09-08 2019-03-28 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Gene therapy for patients with fanconi anemia
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11219695B2 (en) 2016-10-20 2022-01-11 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3574101B1 (de) 2017-01-30 2023-04-19 KWS SAAT SE & Co. KGaA Reparaturtemplatebindung an endonukleasen zur genommanipulation
HUE065174T2 (hu) 2017-02-12 2024-05-28 Biontech Us Inc HLA-alapú módszerek és készítmények, valamint azok felhasználása
EP4361261A3 (de) 2017-03-15 2024-07-10 The Broad Institute Inc. Neuartige cas13b-orthologe crispr-enzyme und systeme
KR20200006054A (ko) 2017-04-12 2020-01-17 더 브로드 인스티튜트, 인코퍼레이티드 신규 타입 vi crispr 오르소로그 및 시스템
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3073848A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3692152A4 (de) 2017-10-04 2021-12-01 The Broad Institute, Inc. Verfahren und zusammensetzungen zur veränderung der funktion und struktur von chromatinschleifen und/oder -domänen
BR112020007444A2 (pt) 2017-10-16 2020-10-20 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. vetores lentivirais para a liberação de pklr para tratar deficiência de piruvato quinase
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
EP3710039A4 (de) 2017-11-13 2021-08-04 The Broad Institute, Inc. Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
JP7197901B2 (ja) * 2018-01-11 2022-12-28 学校法人慈恵大学 Ｈｕｎｔｅｒ症候群の遺伝子治療に使用されるベクタープラスミド、レンチウイルスベクターシステム、細胞、及び、細胞製剤
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
CN116024271A (zh) * 2018-05-31 2023-04-28 康霖生物科技（杭州）有限公司 一种用于中枢神经系统疾病治疗的基因序列构建体
EP3833761A1 (de) 2018-08-07 2021-06-16 The Broad Institute, Inc. Neuartige cas12b-enzyme und systeme
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US11384344B2 (en) 2018-12-17 2022-07-12 The Broad Institute, Inc. CRISPR-associated transposase systems and methods of use thereof
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
SG11202106678PA (en) 2018-12-21 2021-07-29 Biontech Us Inc Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
JP2022516317A (ja) * 2019-01-04 2022-02-25 サンガモ セラピューティクス， インコーポレイテッド ファブリー病の処置のための方法及び組成物
AU2020236735A1 (en) 2019-03-10 2021-10-14 Oxford Biomedica (Uk) Limited Gene therapy compositions and methods for treating parkinson's disease
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
JP2022544688A (ja) 2019-08-16 2022-10-20 マサチューセッツ インスティテュート オブ テクノロジー Ｃｒｉｓｐｒ／ｃａｓ１３を使用する標的化トランススプライシング
IL300263A (en) 2020-08-07 2023-03-01 Spacecraft Seven Llc Plakophilin-2 (PKP2) gene therapy using an AAV vector
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
IL301955A (en) 2020-10-07 2023-06-01 Asklepios Biopharmaceutical Inc Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
AU2021400424A1 (en) 2020-12-14 2023-07-06 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
CN114107396B (zh) * 2021-11-26 2024-02-02 和元智造(上海)基因技术有限公司 慢病毒载体、系统及其应用
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2024010067A1 (ja) * 2022-07-08 2024-01-11 Ｊｃｒファーマ株式会社 中枢神経系疾患の治療のための、核酸分子、ベクター、組換え細胞及び薬剤
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169762A (en) 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
AU665176B2 (en) 1990-09-21 1995-12-21 Novartis Vaccines And Diagnostics, Inc. Packaging cells
JPH06501617A (ja) 1990-09-25 1994-02-24 ジェネンテク，インコーポレイテッド 新規な神経栄養因子
WO1993003143A1 (en) 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
EP0706319A4 (de) * 1993-01-20 1998-04-22 Biotransplant Inc Retrovirale vektoren mit der fähigkeit zur expression multimerer proteine von mehreren translationsinitiations-orten
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5728803A (en) 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
US6103226A (en) * 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
AU3635695A (en) 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
EP0857217B1 (de) 1995-10-16 2005-04-13 Dana-Farber Cancer Institute Neue expressionsvektoren und verfahren zu deren verwendung
CA2237000A1 (en) 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
AU1073797A (en) 1995-11-14 1997-06-05 Somatix Therapy Corporation Joint expression of gtp cyclohydrolase and tyrosine hydroxylase
US6222022B1 (en) 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
JP3385032B2 (ja) * 1996-09-21 2003-03-10 ヴィロメディカ パシフィック リミテッド 遺伝子治療のための改善されたレトロウイルスベクター
PT904392E (pt) * 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
NZ500740A (en) * 1997-05-13 2001-02-23 Univ North Carolina Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
US5834914A (en) 1997-09-08 1998-11-10 Safetran Systems Corporation Railroad crossing gate mechanism control system
US6136597A (en) * 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
JP2001517453A (ja) * 1997-09-23 2001-10-09 オックスフォード バイオメディカ（ユーケイ）リミテッド 方 法
GB2334257B (en) * 1997-12-22 2001-07-04 Oxford Biomedica Ltd Rectroviral vectors
PT1895010E (pt) 1997-12-22 2012-01-25 Oxford Biomedica Ltd Vectores com base no vírus da anemia infecciosa equina (eiav)
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
AU763007B2 (en) 1998-05-22 2003-07-10 Oxford Biomedica (Uk) Limited Retroviral delivery system
US6555342B1 (en) * 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US6958226B1 (en) * 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease

Also Published As

Publication number Publication date
GB0024550D0 (de) 2000-11-22
EP1337655B1 (de) 2010-07-14
CY1110817T1 (el) 2015-06-10
ES2348277T3 (es) 2010-12-02
AU2001292093A1 (en) 2002-04-15
JP4224295B2 (ja) 2009-02-12
EP2180057A1 (de) 2010-04-28
DE60142576D1 (de) 2010-08-26
US20070025970A1 (en) 2007-02-01
WO2002029065A3 (en) 2002-12-27
US7259015B2 (en) 2007-08-21
PT1337655E (pt) 2010-08-25
CA2424738A1 (en) 2002-04-11
DK1337655T3 (da) 2010-09-20
JP2004520016A (ja) 2004-07-08
EP1337655A2 (de) 2003-08-27
WO2002029065A2 (en) 2002-04-11
US20040013648A1 (en) 2004-01-22
US20090111106A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
ATE474058T1 (de) Lentivirale vektoren zur behandlung neurodegenerativer krankheiten
BRPI0211200B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DK1351703T3 (da) Anvendelse af et polypeptid omfattende det ekstracellulære domæne af IL-20RA og IL-20RB til behandling af inflammation
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE60234318D1 (de) Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
CY1107668T1 (el) Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
BR9812357A (pt) Tratamento de distúbio oposicional desafiador
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
BR0209990A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
ATE326964T1 (de) Aminosäurederivate zur behandlung der alzheimer- krankheit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus
NO20045089L (no) Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DK1425295T3 (da) Modificerede peptider og deres anvendelse til behandling af autoimmune sygdomme
EP1760087A4 (de) Neuer proteinkomplex und anwendungen davon
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
DE50210473D1 (de) Phosphinat-peptidanaloga als inhibitoren der procollagen-c-proteinase (pcp) zur behandlung von fibrotischen erkrankungen